Top Line

Novavax’s COVID-19 vaccine, already available for use in 170 countries and best known for being a non-mRNA vaccine option, was launched in February for use in the US and 10 other countries within 90 days. Can be approved, CEO Stanley Arkey said CNBC Monday.

important facts

- Advertisement -

Maryland-based biotechnology company Presented Erck said its final data package to the US Food and Drug Administration on New Year’s Eve, but will not be able to request emergency use authorization until January 31, after which the company expects a decision within a month.

Erk said the company expects its vaccine to be approved for use in several countries over the next 90 days, as the vaccine was recently presented for use in Australia, Canada, New Zealand, Singapore, South Africa and the UK. and the World Health Organization.

The vaccine, which stimulates the immune system using nanoparticles instead of mRNA, could help convince those who are skeptical of mRNA technology for vaccination, Erk said.

- Advertisement -